Soluble guanylate cyclase activators

US9284301B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Darby Schmidt · Arlington, US
• Subharekha Raghavan · Teaneck, US
• John E. Stelmach · Westfield, US
• Jian Guo · Lawrence, US
• Jonathan Groeper · Metuchen, US
• Linda Brockunier · Orange, US
• Keith Rosauer · New Hampton, US
• Hong Shen · Shanghai, CN
• Rui Liang · Plainsboro, US
• Fa-Xiang Ding · Staten Island, US

Key dates

• Filing date: Mar 22, 2011
• Grant date: Mar 15, 2016
• Expiry date: Mar 22, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.